Related Experiment Video
Updated: Mar 18, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation
Safoora Fatima1, Anne Holbrook2, Sam Schulman3
1Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
Insights
This study validated a decision aid for atrial fibrillation (AF) patients choosing antithrombotic agents. The tool improved patient confidence and knowledge regarding stroke prevention medications.
Area of Science:
- Cardiology
- Pharmacology
- Health Informatics
Background:
- Atrial fibrillation (AF) necessitates stroke prevention using various antithrombotic agents.
- Patient decision-making can be complex due to multiple treatment options.
- Decision aids can support informed choices for patients with AF.
Purpose of the Study:
- To validate a decision aid for patients selecting antithrombotic therapies for AF.
- To assess the aid's impact on patient confidence, knowledge, and understanding of treatment options.
Main Methods:
- Prospective study involving patients aged 60 years or older.
- Decision aid presented information on AF, aspirin, warfarin, and direct-acting oral anticoagulants (DOACs).
- Primary outcome: decisional conflict; Secondary outcomes: knowledge, clarity, helpfulness, and comprehensiveness ratings.
Main Results:
- Eighty-one patients participated; mean age 75.2 years.
- Decision aid use resulted in low decisional conflict (7.2/100).
- Significant improvement in knowledge scores (7.4 to 9.3/10) and high ratings for helpfulness, clarity, and comprehensiveness.
Conclusions:
- The validated decision aid enhances patient participation in shared decision-making for AF anticoagulation.
- Addresses a critical gap in medication safety for AF patients.
- Further research needed to assess the impact of decision aids on clinical choices and outcomes.
Background:
Multiple antithrombotic agents are available for stroke prevention in atrial fibrillation (AF). A decision aid can assist patients in making informed decisions that best serves their needs.
Objective:
To validate a decision aid to assist patients in choosing between antithrombotic agents (antiplatelets, warfarin, direct-acting oral anticoagulants (DOACs)) for AF.
Methods:
Patients (60years or older) were recruited for this prospective study. The decision aid presented descriptions related to AF, then charts portraying important outcomes for comparisons between 1) no treatment, aspirin and anticoagulants, 2) warfarin versus DOACs, and 3) DOAC versus DOAC. The primary outcome was confidence in making treatment decisions. The secondary outcomes included change in knowledge scores, ratings of clarity, helpfulness and comprehensiveness.
Results:
Eighty-one patients (mean age 75.2 [SD 7.5], 77% taking an anticoagulant) participated. After using the decision aid, mean decisional conflict score was low at 7.2 [SD 10.8] on a scale from 1 to 100. Mean knowledge score (total possible 10) improved from 7.4 [SD 1.7] to 9.3 [SD 1.0] (p<0.001). The mean helpfulness score in making a treatment choice was high at 6.2 [SD 0.9] on a scale from 1 to 7. No participant found the decision aid difficult to understand. Information in the decision aid was rated as good or excellent in terms of clarity and comprehensiveness.
Conclusions:
Our decision aid addresses a key medication safety gap - assisting patients to participate in shared decisions about anticoagulation. Future research is required to evaluate how decision aids influence actual choices and clinical outcomes.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins

